Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae

Nakai, Hazuki; Hagihara, Mao; Kato, Hideo; Hirai, Jun; Nishiyama, Naoya; Koizumi, Yusuke; Sakanashi, Daisuke; Suematsu, Hiroyuki; Yamagishi, Yuka

doi:10.1016/j.jiac.2016.02.004

Cited by 63 publications

(44 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous antibiotic use seemed to be associated with the emergence of ESBL producing uropathogens (OR,3.07; 95% CI,1. 46-6.45), and this is consistent with many studies [30][31][32]. Actually, proper use of antibiotics reduces the emergence of multidrug-resistant bacteria [33].…”

Section: Discussionsupporting

confidence: 89%

“…Urinary Tract Infection (UTI) is one of the most common infections worldwide, and as many others, there is an increasing resistance among urinary tract pathogens to conventional drugs used to treat them [5].…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, ESBL-producing organisms bear co-resistance to other antimicrobial agent's classes, such as aminoglycosides, sulfonamide and fluoroquinolones. Therefore, these multi-drug resistant organisms make treatment options and infection control challenging, and initial empiric therapy is often ineffective and associated with increased morbidities, hospitalization period, and rising medical costs [5].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence and Risk Factors of Extended Spectrum Beta-Lactamase-Producing Uropathogens among UTI Patients in the Governmental Hospitals of North West Bank: A Cross-Sectional Study

Taha¹,

Shtawi²,

Jaradat³

et al. 2018

J Infect Dis Preve Med

View full text Add to dashboard Cite

Background: Urinary tract infections caused by Extended Spectrum Beta-Lactamase producing organisms (UTI-ESBL) are increasing in incidence and pose a great threat to modern medicine. The objective of this study was to assess the prevalence and risk factors of Extended Spectrum Beta-Lactamase (ESBL)-producing uropathogens among patients with urinary tract infections in the north of West Bank and to determine the antimicrobial susceptibility profile of the isolated bacteria. Methods: A total of 427 patients who were attending the governmental hospitals in the northern cities of the West Bank were included in the study. They were older than 12 years and diagnosed with UTI in the period from June 2017 to September 2017. Isolated bacteria was collected from the microbiology labs of the respective hospitals and tested for the ESBL production and their antibiotic susceptibilities were determined. Information regarding the risk factors was collected from the patient ' s medical records. Univariate analyses were performed for potential risk factors for the development of UTI-ESBL, and then multivariate analyses were performed for all significant variables. Results: Out of the 427 urine cultures screened for ESBL, 163 (38.4%) were confirmed to be ESBL producers. E. coli was the most frequent uropathogen. K. pneumoniae produced the highest rate of ESBL (54.9%), followed by E. coli (42.5%), and Proteus mirabilis (7.14%). Patients with recurrent UTI had 5 times relative risk of having ESBL producing uropathogens (odd ratio (OR), 4.7) followed by previous antibiotic use (OR, 3.07), hemodialysis (OR, 2.92), chronic kidney disease (OR, 2.69) and finally diabetes mellitus (OR, 1.87). ESBL isolates were susceptible to fosfomycin (100%), nitrofurantoin (93.9%), pipracillin/tazobactam (94.5%), ertapenem (98.2%), meropenem (98.8%), and amikacin (93.9%). Conclusion: The prevalence of ESBL-producing uropathogens was 38.4%. Recurrent UTI appeared to be the strongest risk factor for ESBL-UTI. ESBL-producing uropathogens were highly susceptible to amikacin, nitrofurantoin, and much more to fosfomycin and piperacillin/tazobactam in addition to carbapenems.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and Risk Factors of Extended Spectrum Beta-Lactamase-Producing Uropathogens among UTI Patients in the Governmental Hospitals of North West Bank: A Cross-Sectional Study

Taha¹,

Shtawi²,

Jaradat³

et al. 2018

J Infect Dis Preve Med

View full text Add to dashboard Cite

show abstract

“…The emergence of multidrug-resistant E. coli has been increasingly reported (Paterson and Bonomo, 2005). Nearly, 63% of total E. coli isolates in many countries were able to produce extendedspectrum beta-lactamase and the majority belonged to E. coli isolated from the ICU patients (Magiorakos et al, 2012;Nakai et al, 2016). In this work, all E. coli isolates were resistant to at least six antibiotics of different classes.…”

Section: Discussionmentioning

confidence: 69%

Cell free preparations of probiotics exerted antibacterial and antibiofilm activities against multidrug resistant E. coli

Abdelhamid

Esaam

Hazaa

2018

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

The sharp increase in antibiotic resistance imposes a global threat to human health and the discovery of effective antimicrobial alternatives is needed. The use of probiotics to combat bacterial pathogens has gained a rising interest. Pathogenic is causative of multiple clinical syndromes such as diarrheal diseases, meningitis and urinary tract infections. In this work, we evaluated the efficacy of probiotics to control multidrug-resistant and reduce their ability to form biofilms. Six resistant to at least five antibiotics (Ceftazidime, Ampicillin, Clarithromycin, Amoxicillin + Clavulanic Acid and Ceftriaxone) were isolated in this work. Preparations of cell-free spent media (CFSM) of six probiotics belonging to the genus and which were grown in Man-Rogosa-Sharpe (MRS) broth exhibited strong antibacterial activity (inhibition zones of 11.77-23.10 mm) against all isolates. Two isolates, namely WW1 and IC2, which were most resistant to all antibiotics were subjected to antibiofilm experiments. Interestingly, the CFSM of MRS fermented by all probiotics resulted in inhibition of biofilm formation while caused highest inhibition (57.94%) in case of IC2 biofilms and was responsible for 64.57% reduction of WW1 biofilms. On the other hand, CFSM of skim milk fermented by and exhibited a slight inhibitory activity against IC2 isolate (inhibition percentage of 31.52 and 17. 68, respectively) while WW1 isolate biofilms was reduced by CFSM of milk fermented by and (70.81 and 69.49 reduction percentage, respectively). These results support the effective use of probiotics as antimicrobial alternatives and to eradicate biofilms formed by multidrug-resistant .

show abstract

“…Recent studies have shown that the prevalence of ESBL-EC in different countries can be as high as 63%, with the highest rate belonging to E. coli isolated from ICU patients in Turkey (Hawser et al, 2009; Magiorakos et al, 2012; Nakai et al, 2016). Reports indicated that ESBL-EC rates are generally very high in Turkey; however, previous studies generally do not take the clonal relationships of the isolates into account (Kacmaz et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

In vitro Effectiveness of Commercial Bacteriophage Cocktails on Diverse Extended-Spectrum Beta-Lactamase Producing Escherichia coli Strains

2016

View full text Add to dashboard Cite

The objective of this study is to determine the in vitro susceptibility of Georgian bacteriophage cocktails on multidrug resistant (MDR) extended-spectrum beta-lactamase producing Escherichia coli (ESBL-EC) isolated from patients’ blood and urine cultures. A total of 615 E. coli isolates were included in this study. Phene Plate (PhP)-typing and phylogenetic grouping were used for the typing. Antimicrobial resistance profiles and ESBL production of all isolates were confirmed according to Clinical and Laboratory Standards Institute (CLSI) criteria. The activities of four bacteriophage cocktails (Enko-phage, SES-bacteriophage, Pyo-bacteriophage, and Intesti-bacteriophage) were determined against 142 ESBL-EC using in vitro spot tests. According to this, Enko-phage were active against 87.3% of the tested strains while that ratio was 81.7% for Intesti-bacteriophage, 81.7% for Pyo-bacteriophage, and 59.2% for SES-bacteriophage cocktails. Based on the contingency tests, the phage cocktails were observed to be statistically significantly (p < 0.001) more effective on ESBL-EC strains belonging to phylogenetic groups D and B2. The employed phage cocktails were found to be affective against all tested resistant types. These results are promising especially for the infections that are caused by MDR pathogens that are difficult to treat. As this is a preliminary step to the potential clinical trials to be designed for the country, in vitro confirmation of their success on a MDR ESBL-EC collection should be accepted as an initial action, which is encouraging to consider clinical trials of phage therapy especially in countries which are not introduce phage therapy.

show abstract

Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae

Cited by 63 publications

References 28 publications

Prevalence and Risk Factors of Extended Spectrum Beta-Lactamase-Producing Uropathogens among UTI Patients in the Governmental Hospitals of North West Bank: A Cross-Sectional Study

Prevalence and Risk Factors of Extended Spectrum Beta-Lactamase-Producing Uropathogens among UTI Patients in the Governmental Hospitals of North West Bank: A Cross-Sectional Study

Cell free preparations of probiotics exerted antibacterial and antibiofilm activities against multidrug resistant E. coli

In vitro Effectiveness of Commercial Bacteriophage Cocktails on Diverse Extended-Spectrum Beta-Lactamase Producing Escherichia coli Strains

Contact Info

Product

Resources

About